Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Disparities in Cancer Mortality and Incidence Among American Indians and Alaska Natives in the United States
White, Mary C. , Espey, David K., Swan, Judith, Wiggins, Charles L. , Eheman, Christie R., Kaur, Judith S.

American Journal of Public Health | April 22, 2014 | Volume: 104 | Issue: S3 | Pages: S377-S387

10.2105/ajph.2013.301673 | PMID 24754660 Get It

Objectives. We used improved data on American Indian and Alaska Native (AI/AN) ancestry to provide an updated and comprehensive description of cancer mortality and incidence among AI/AN populations from 1990 to 2009. Methods. We linked the National Death Index and central cancer registry records independently to the Indian Health Service (IHS) patient registration database to improve identification of AI/AN persons in cancer mortality and incidence data, respectively. Analyses were restricted to non-Hispanic persons residing in Contract Health Service Delivery Area counties in 6 geographic regions of the United States. We compared age-adjusted mortality and incidence rates for AI/AN populations with White populations using rate ratios and mortality-to-incidence ratios. Trends were described using joinpoint analysis. Results. Cancer mortality and incidence rates for AI/AN persons compared with Whites varied by region and type of cancer. Trends in death rates showed that greater progress in cancer control was achieved for White populations compared with AI/AN populations over the last 2 decades. Conclusions. Spatial variations in mortality and incidence by type of cancer demonstrated both persistent and emerging challenges for cancer control in AI/AN populations.
Phenotypic and Functional Maturation of Dendritic Cells Mediated by Heparan Sulfate
Kodaira, Yuzo , Nair, Smita K. , Wrenshall, Lucile E. , Gilboa, Eli , Platt, Jeffrey L.

The Journal of Immunology | April 22, 2014 | Volume: 165 | Issue: 3 | Pages: 1599-1604

10.4049/jimmunol.165.3.1599 | PMID 10903769 Get It

Abstract Primary immune responses are thought to be induced by dendritic cells. To promote such responses, dendritic cells must be activated by exogenous agonists, such as LPS, or by products of activated leukocytes, such as TNF-α and IL-1. How dendritic cells might be activated in the absence of exogenous stimuli, or without the immediate presence of activated leukocytes, as might occur in immunity to tumor cells or transplants, is unknown. We postulated that heparan sulfate, an acidic, biologically active polysaccharide associated with cell membranes and extracellular matrices, which is rapidly released under conditions of inflammation and tissue damage, might provide such a stimulus. Incubation of immature murine dendritic cells with heparan sulfate induced phenotypic maturation evidenced by up-regulation of I-A, CD40, CD54 (ICAM-1), CD80 (B7-1), and CD86 (B7-2). Dendritic cells exposed to heparan sulfate exhibited a markedly lowered rate of Ag uptake and increased allostimulatory capacity. Stimulation of dendritic cells with heparan sulfate induced release of TNF-α, IL-1β, and IL-6, although the maturation of dendritic cells was independent of these cytokines. These results suggest that soluble heparan sulfate chains, as products of the degradation of heparan sulfate proteoglycan, might induce maturation of dendritic cells without exogenous stimuli, thus contributing to the generation and maintenance of primary immune responses.
TGF-β2 Reduces Demyelination, Virus Antigen Expression, and Macrophage Recruitment in a Viral Model of Multiple Sclerosis
Drescher, Kristen M. , Murray, Paul D., Lin, Xiaoqi , Carlino, J A, Rodriguez, Moses

The Journal of Immunology | April 22, 2014 | Volume: 164 | Issue: 6 | Pages: 3207-3213

10.4049/jimmunol.164.6.3207 | PMID 10706712 Get It

Abstract TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler’s murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.
Central Role of Thrombospondin-1 in the Activation and Clonal Expansion of Inflammatory T Cells
Vallejo, Abbe N. , Mügge, Lars O., Klimiuk, Piotr Adrian , Weyand, Cornelia M. , Goronzy, Jörg J.

The Journal of Immunology | April 22, 2014 | Volume: 164 | Issue: 6 | Pages: 2947-2954

10.4049/jimmunol.164.6.2947 | PMID 10706681 Get It

Abstract Thrombospondin-1 (TSP) is a transiently expressed matricellular protein known to promote chemotaxis of leukocytes to inflammatory sites. However, TSP and its receptor CD36 are abundantly expressed in chronically inflamed tissues such as the rheumatoid synovium. Here, we show that TSP provides the costimulatory signal that is necessary for the activation of autoreactive T cells. Data presented reveal that TSP-mediated costimulation is achieved through its independent interaction with CD36 on APCs and with CD47 on T cells. We propose that a CD47-TSP-CD36 trimolecular complex is a novel costimulatory pathway that significantly decreases the threshold of T cell activation. Consistent with the paradigm that lesions in rheumatoid synovitis are sites of antigenic recognition, the characteristic focal expression of TSP on APCs such as macrophages and fibroblast-like synoviocytes suggest a central role of TSP in the expansion of tissue-infiltrating T cells.
Cutting Edge: WIP, a Binding Partner for Wiskott-Aldrich Syndrome Protein, Cooperates with Vav in the Regulation of T Cell Activation
Savoy, Doris N., Billadeau, Daniel D. , Leibson, Paul J.

The Journal of Immunology | April 22, 2014 | Volume: 164 | Issue: 6 | Pages: 2866-2870

10.4049/jimmunol.164.6.2866 | PMID 10706671 Get It

Abstract Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP), specifically binds to a region of WASp that is frequently mutated in Wiskott-Aldrich syndrome. Due to the similar phenotypes of WASp- and Vav-deficient T cells, and the putative importance of the WIP/WASp complex in mediating normal signals from the TCR, we investigated the role of WIP in regulating NF-AT/AP-1-mediated gene transcription. We show that WIP has the ability to enhance Vav-mediated activation of NF-AT/AP-1 gene transcription. In addition, we provide evidence that the interaction of WIP with WASp is necessary, but not sufficient for the ability of WIP to regulate NF-AT/AP-1 activity. Finally, we have identified a region in WIP required for its regulation of NF-AT/AP-1 activity. Our data suggests that the WIP-WASp interaction is important for NF-AT/AP-1-mediated gene transcription, and that defects seen in the activation of T cells from WAS patients may be due to the inability of these cells to form a functional WIP/WASp-signaling complex.
Closed-Loop Artificial Pancreas Systems: Physiological Input to Enhance Next-Generation Devices
Kudva, Yogish C. , Carter, Rickey E. , Basu, Rita , Basu, Ananda , Cobelli, Claudio , Carter, Rickey E

Diabetes Care | April 22, 2014 | Volume: 37 | Issue: 5 | Pages: 1184-1190

10.2337/dc13-2066 | PMID 24757225 Get It

To provide an understanding of both the preclinical and clinical aspects of closed-loop artificial pancreas systems, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, the Bench narrative provides an in-depth understanding of insulin-glucose-glucagon physiology in conditions that mimic the free-living situation to the extent possible in type 1 diabetes that will help refine and improve future closed-loop system algorithms. In the Clinic narrative, Doyle and colleagues compare and evaluate technology used in current closed-loop studies to gain further momentum toward outpatient trials and eventual approval for widespread use.
Abdominal Pain, Flank Pain, Blurry Vision, and Lower Extremity Weakness in a 16‐Year‐Old Female
Wu, Yifan , Fidler, Mary E., Cramer, Carl H. , Bower, Thomas C., Qian, Qi , Mao, Michael A.

Arthritis Care & Research | April 22, 2014 | Volume: 66 | Issue: 9 | Pages: 1423-1429

10.1002/acr.22348 | PMID 24757018 Get It

An Alternative for Surgical Management of Calcific Aortic Valve Stenosis: Sutureless Valve Implants
Michler, Robert E. , Enriquez‐Sarano, Maurice , Schaff, Hartzell V. , Suri, Rakesh M. , Michelena, Héctor I. , Enriquez-Sarano, Maurice , Schaff, Hartzell

Journal of Cardiac Surgery | April 22, 2014 | Volume: 29 | Issue: 4 | Pages: 490-493

10.1111/jocs.12333 | PMID 24750424 Get It

Filter Neuroprotection of a Single Patent Internal Carotid Artery During Transapical Aortic Valve Implantation
Sarangi, Siddharth, Bresnahan, John F., Mario, Gössl, Suri, Rakesh M. , Bruce, Charles J.

Journal of Cardiac Surgery | April 22, 2014 | Volume: 30 | Issue: 3 | Pages: 260-262

10.1111/jocs.12347 | PMID 24750251 Get It

The neurobiological basis of cognitive impairment in Parkinson's disease
Halliday, Glenda M. , Leverenz, James B. , Schneider, Jay S. , Adler, Charles H. , Halliday, Glenda , Leverenz, James B

Movement Disorders | April 22, 2014 | Volume: 29 | Issue: 5 | Pages: 634-650

10.1002/mds.25857 | PMID 24757112 Get It

ABSTRACTThe recent formalization of clinical criteria for Parkinson's disease with dementia (PDD) codifies many studies on this topic, including those assessing biological correlates. These studies show that the emergence of PDD occurs on the background of severe dopamine deficits with, the main pathological drivers of cognitive decline being a synergistic effect between alpha‐synuclein and Alzheimer's disease pathology. The presence of these pathologies correlates with a marked loss of limbic and cortically projecting dopamine, noradrenaline, serotonin, and acetylcholine neurons, although the exact timing of these relationships remains to be determined. Genetic factors, such as triplications in the α‐synuclein gene, lead to a clear increased risk of PDD, whereas others, such as parkin mutations, are associated with a reduced risk of PDD. The very recent formalization of clinical criteria for PD with mild cognitive impairment (PD‐MCI) allows only speculation on its biological and genetic bases. Critical assessment of animal models shows that chronic low‐dose MPTP treatment in primates recapitulates PD‐MCI over time, enhancing the current biological concept of PD‐MCI as having enhanced dopamine deficiency in frontostriatal pathways as well as involvement of other neurotransmitter systems. Data from other animal models support multiple transmitter involvement in cognitive impairment in PD. Whereas dopamine dysfunction has been highlighted because of its obvious role in PD, the role of the other neurotransmitter systems, neurodegenerative pathologies, and genetic factors in PD‐MCI remains to be fully elucidated. © 2014 International Parkinson and Movement Disorder Society